01/11/2026
Dr Archie De-Bunker with an RMS house call.
Dr Mercola, sadly, is well known for sensationalist claims. And here’s another (with a visual of someone’s hand over the opposite side of where their liver would be, ironically) on “hydrogen therapy”. Well, while these researchers explore, don’t wait. Here are some facts you need to know if you have MASLD (aka NAFLD) type fatty liver:
An important additional clarification—because delay matters here.
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is not a benign condition that can be “supported” indefinitely with supplements. In a meaningful subset of patients, prolonged fatty liver does progress—from simple steatosis to metabolic dysfunction–associated steatohepatitis, fibrosis, cirrhosis, and ultimately liver failure or hepatocellular carcinoma (primary liver cancer). This progression is often silent.
That’s why false reassurance is dangerous.
Milk thistle (silymarin) is frequently promoted as a liver “cure-all.” The reality is far more modest. While it has antioxidant properties and may improve liver enzyme levels, it has not been shown to reliably reduce liver fat, reverse fibrosis, or halt disease progression. Normalizing blood tests without addressing liver fat can create a false sense of security while underlying pathology continues.
The same caution applies to speculative approaches such as hydrogen-based therapies. Mechanistic hypotheses and early-phase studies do not substitute for robust, long-term clinical outcome data.
To be very clear:
The primary, evidence-based treatment for metabolic dysfunction–associated steatotic liver disease is intentional, sustained weight loss and metabolic improvement, leading to evacuation of fat from the liver. Even 5–10% reduction in body weight has been shown repeatedly to reduce liver fat, improve inflammation, and slow or reverse early disease.
Supplements and experimental therapies may one day play an adjunctive role. But they do not replace the urgency of addressing energy excess, insulin resistance, and visceral adiposity now.
Delaying effective treatment in favor of unproven “supportive” approaches risks allowing a reversible condition to become irreversible.
Bottom line:
Metabolic dysfunction–associated steatotic liver disease is common, serious, and treatable—but only if we act on what actually works. Clarity matters. Timing matters. Outcomes depend on it.